Immunogenicity and immune memory of a nonadjuvanted quadrivalent meningococcal glycoconjugate vaccine in infants.

Immunogenicity and immune memory of a nonadjuvanted quadrivalent meningococcal glycoconjugate vaccine in infants.

BACKGROUND: The highest rate of invasive meningococcal disease is among children under 2 years of age. There is currently no licensed quadrivalent (serogroups A, C, W-135, and Y) meningococcal glycoconjugate vaccine approved for infants. We evaluated the immunogenicity and reactogenicity of a novel...

Description complète

Détails bibliographiques
Auteurs principaux:	Perrett, K, Snape, MD, Ford, K, John, T, Yu, L, Langley, J, McNeil, S, Dull, P, Ceddia, F, Anemona, A, Halperin, SA, Dobson, S, Pollard, A
Format:	Journal article
Langue:	English
Publié:	2009

Documents similaires

Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants: a randomized controlled trial.
par: Snape, MD, et autres
Publié: (2008)

Immunogenicity and safety of a quadrivalent meningococcal polysaccharide CRM conjugate vaccine in infants and toddlers
par: Miguel Tregnaghi, et autres
Publié: (2014-09-01)

Persistence of the immune response at 5 years of age following infant immunisation with investigational quadrivalent MenACWY conjugate vaccine formulations
par: Khatami, A, et autres
Publié: (2012)

Persistence of the immune response at 5 years of age following infant immunisation with investigational quadrivalent MenACWY conjugate vaccine formulations.
par: Khatami, A, et autres
Publié: (2012)

Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: an observer-blind, phase 3 randomised clinical trial.
par: Read, R, et autres
Publié: (2014)

Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: An observer-blind, phase 3 randomised clinical trial
par: Read, R, et autres
Publié: (2014)

Immunogenicity and Safety of MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared with a Nonadjuvanted, Quadrivalent Influenza Vaccine in Adults 50–64 Years of Age
par: Airi Poder, et autres
Publié: (2023-09-01)

Randomized clinical trial to evaluate the immunogenicity of quadrivalent meningococcal conjugate and polysaccharide vaccines in adults in the United kingdom.
par: Ramasamy, M, et autres
Publié: (2014)

Quadrivalent meningococcal conjugate vaccines
par: Pace, D, et autres
Publié: (2009)

Quadrivalent meningococcal conjugate vaccines.
par: Pace, D, et autres
Publié: (2009)

Current safety issues with quadrivalent meningococcal conjugate vaccines
par: Tanya R. Myers, et autres
Publié: (2018-05-01)

Demonstration of immunologic memory using serogroup C meningococcal glycoconjugate vaccine.
par: Snape, MD, et autres
Publié: (2009)

Safety and immunogenicity of quadrivalent meningococcal polysaccharide vaccine (MPV ACYW135) compared with quadrivalent meningococcal conjugate vaccine (Menactra®) in Malian children
par: Samba O. Sow, et autres
Publié: (2023-08-01)

Safety and immunogenicity of conjugate quadrivalent meningococcal vaccination after hematopoietic cell transplantation
par: Matthew P. Cheng, et autres
Publié: (2018-06-01)

Persistence of bactericidal antibodies following early infant vaccination with a serogroup B meningococcal vaccine and immunogenicity of a preschool booster dose.
par: Snape, MD, et autres
Publié: (2013)

Persistence of bactericidal antibodies following early infant vaccination with a serogroup B meningococcal vaccine and immunogenicity of a preschool booster dose
par: Snape, M, et autres
Publié: (2013)

High-dimensional assessment of B-cell responses to quadrivalent meningococcal conjugate and plain polysaccharide vaccine.
par: O'Connor, D, et autres
Publié: (2017)

Immunogenicity and safety of a novel quadrivalent meningococcal conjugate vaccine (MenACWY-CRM) in healthy Korean adolescents and adults
par: Hoan Jong Lee, et autres
Publié: (2014-11-01)

An overview of the meningococcal disease and impact of the quadrivalent meningococcal conjugate vaccine
par: Asmaa Alrobai, et autres
Publié: (2021-12-01)

MEMORY B CELL RESPONSES FOLLOWING IMMUNISATION WITH POLYSACCHARIDE AND CONJUGATE QUADRIVALENT MENINGOCOCCAL ACYW135 VACCINES IN HEALTHY ADULT VOLUNTEERS
par: Maheshi, R, et autres
Publié: (2010)

Immunogenicity and immunologic memory of meningococcal C conjugate vaccine in premature infants.
par: Collins, C, et autres
Publié: (2005)

Development of a glycoconjugate vaccine to prevent meningitis in Africa caused by meningococcal serogroup X.
par: Micoli, F, et autres
Publié: (2013)

Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial.
par: Gossger, N, et autres
Publié: (2012)

Alternative vaccine administration by powder injection: Needle-free dermal delivery of the glycoconjugate meningococcal group Y vaccine.
par: Nikolas T Weissmueller, et autres
Publié: (2017-01-01)

Immunogenicity phase II study evaluating booster capacity of nonadjuvanted AKS-452 SARS-Cov-2 RBD Fc vaccine
par: David G. Alleva, et autres
Publié: (2024-02-01)

A Phase 3B, Open-Label Study to Evaluate the Immunogenicity and Safety of the Quadrivalent Meningococcal Nimenrix® Vaccine When Given to Healthy Infants at 3 and 12 Months of Age
par: Susanna Koski, et autres
Publié: (2025-01-01)

Meningococcal polysaccharide-protein conjugate vaccines.
par: Snape, MD, et autres
Publié: (2005)

An update of clinical experience with the quadrivalent meningococcal ACWY-CRM conjugate vaccine
par: Pavitra Keshavan, et autres
Publié: (2018-10-01)

Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine Versus Nimenrix in Healthy Adolescents: A Randomized Phase IIIb Multicenter Study
par: Javier Díez-Domingo, et autres
Publié: (2024-07-01)

Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT): A review of the evidence and expert opinion
par: Silvia Ricci, et autres
Publié: (2023-12-01)

Use of a booster dose of capsular group C meningococcal glycoconjugate vaccine to demonstrate immunologic memory in children primed with one or two vaccine doses in infancy
par: Pace, D, et autres
Publié: (2016)

Glycoconjugates: What It Would Take To Master These Well-Known yet Little-Understood Immunogens for Vaccine Development
par: Fikri Avci, et autres
Publié: (2019-10-01)

Plasma and memory B-cell kinetics in infants following a primary schedule of CRM 197-conjugated serogroup C meningococcal polysaccharide vaccine.
par: Kelly, D, et autres
Publié: (2009)

Immunogenicity and safety of a combination pneumococcal-meningococcal vaccine in infants: a randomized controlled trial.
par: Buttery, J, et autres
Publié: (2005)

Alternative vaccine administration by powder injection: Needle-free dermal delivery of the glycoconjugate meningococcal group Y vaccine
par: Weissmueller, N, et autres
Publié: (2017)

Cost-effectiveness of alternate strategies for childhood immunization against meningococcal disease with monovalent and quadrivalent conjugate vaccines in Canada.
par: Thomas E Delea, et autres
Publié: (2017-01-01)

Serogroup C meningococcal glycoconjugate vaccine in adolescents: persistence of bactericidal antibodies and kinetics of the immune response to a booster vaccine more than 3 years after immunization.
par: Snape, MD, et autres
Publié: (2006)

Serogroup c meningococcal glycoconjugate vaccine in adolescents: persistence of bactericidal antibodies and kinetics of the immune response to a booster vaccine more than 3 years after immunization
par: Snape, M, et autres
Publié: (2006)

Persistence of immunity following a booster dose of Haemophilus influenzae type B-Meningococcal serogroup C glycoconjugate vaccine: follow-up of a randomized controlled trial.
par: Khatami, A, et autres
Publié: (2011)

Assessment of Reactogenicity and Immunogenicity of the Quadrivalent Live Attenuated Influenza Vaccine
par: D. A. Lioznov, et autres
Publié: (2018-06-01)